Morgan Stanley Design Therapeutics, Inc. Transaction History

Morgan Stanley

$1.23 Trillion
Q1 2024

A detailed history of Morgan Stanley transactions in Design Therapeutics, Inc. stock. As of the latest transaction made, Morgan Stanley holds 478,092 shares of DSGN stock, worth $1.6 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

478,092

Previous 543,481 12.03%

Holding current value

$1.6 Million

Previous $1.44 Million 33.75%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$2.27 - $4.03 $148,433 - $263,517	-65,389 Reduced 12.03%	478,092 $1.93 Million
Q4 2023 Feb 13, 2024	BUY	$1.99 - $2.76 $364,613 - $505,695	183,223 Added 50.86%	543,481 $1.44 Million
Q3 2023 Nov 15, 2023	BUY	$2.05 - $8.14 $347,454 - $1.38 Million	169,490 Added 88.85%	360,258 $850,000
Q2 2023 Aug 14, 2023	BUY	$4.99 - $7.64 $605,741 - $927,427	121,391 Added 174.97%	190,768 $1.2 Million
Q1 2023 May 15, 2023	BUY	$5.5 - $9.77 $153,741 - $273,100	27,953 Added 67.48%	69,377 $400,000

Q4 2022 Feb 14, 2023	SELL	$7.86 - $17.2 $137,636 - $301,189	-17,511 Reduced 29.71%	41,424 $425,000
Q3 2022 Nov 14, 2022	BUY	$14.09 - $25.57 $283,251 - $514,033	20,103 Added 51.77%	58,935 $985,000
Q2 2022 Oct 27, 2022	BUY	$9.91 - $17.33 $257,818 - $450,857	26,016 Added 203.0%	38,832 $544,000
Q2 2022 Aug 15, 2022	BUY	$9.91 - $17.33 $257,818 - $450,857	26,016 Added 203.0%	38,832 $544,000
Q1 2022 Oct 27, 2022	SELL	$11.17 - $20.89 $290,598 - $543,474	-26,016 Reduced 67.0%	12,816 $207,000
Q1 2022 May 13, 2022	SELL	$11.17 - $20.89 $5,450 - $10,194	-488 Reduced 3.67%	12,816 $207,000
Q4 2021 Feb 14, 2022	BUY	$13.64 - $21.41 $80,476 - $126,319	5,900 Added 79.69%	13,304 $285,000
Q3 2021 Nov 15, 2021	BUY	$13.99 - $20.03 $103,581 - $148,302	7,404 New	7,404 $108,000

Others Institutions Holding DSGN

# of Institutions

Shares Held

30.5M

Call Options Held

100

Put Options Held

100

View Full List

About Design Therapeutics, Inc.

Ticker DSGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,807,900
Market Cap $187M
Description
Design Therapeutics, Inc. a preclinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of genetic diseases caused by nucleotide repeat expansions. The company's portfolio of products comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ syste...

More about DSGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account